Tagrisso for EGFR-mutant non-small cell lung cancer
Quick answer: Tagrisso is used for EGFR-mutant non-small cell lung cancer as part of a egfr tyrosine kinase inhibitor (3rd generation) treatment regimen. Osimertinib irreversibly binds mutant EGFR including T790M resistance mutation blocking tumor cell proliferation The specific dosing for EGFR-mutant non-small cell lung cancer is determined by your prescriber based on individual factors.
Why is Tagrisso used for EGFR-mutant non-small cell lung cancer?
Tagrisso belongs to the EGFR tyrosine kinase inhibitor (3rd generation) class. Osimertinib irreversibly binds mutant EGFR including T790M resistance mutation blocking tumor cell proliferation This action makes it useful for treating or managing EGFR-mutant non-small cell lung cancer in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Tagrisso is the right choice for a specific patient depends on the type and severity of EGFR-mutant non-small cell lung cancer, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for EGFR-mutant non-small cell lung cancer
Common adult dosing range: 80 mg once daily. The actual dose for EGFR-mutant non-small cell lung cancer depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Tagrisso medicine page.
What to expect
Tagrisso treatment for EGFR-mutant non-small cell lung cancer typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on EGFR-mutant non-small cell lung cancer
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Tagrisso is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all EGFR tyrosine kinase inhibitor (3rd generation) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Tagrisso
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Tagrisso full prescribing information · All EGFR tyrosine kinase inhibitor (3rd generation) alternatives
Frequently asked questions
How effective is Tagrisso for EGFR-mutant non-small cell lung cancer?
Effectiveness varies by individual response, dose, and severity. Tagrisso is one of several treatment options for EGFR-mutant non-small cell lung cancer, supported by clinical evidence within the egfr tyrosine kinase inhibitor (3rd generation) class. Discuss expected response with your prescriber.
How long do I need to take Tagrisso for EGFR-mutant non-small cell lung cancer?
Treatment duration depends on the nature of EGFR-mutant non-small cell lung cancer — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Tagrisso when used for EGFR-mutant non-small cell lung cancer?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Tagrisso for EGFR-mutant non-small cell lung cancer?
Yes. Multiple medicines and non-drug options exist for EGFR-mutant non-small cell lung cancer. Alternatives within the egfr tyrosine kinase inhibitor (3rd generation) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.